<DOC>
	<DOC>NCT00576589</DOC>
	<brief_summary>The study is designed to assess whether repeated dosing with CE-326,597 will cause patients with asymptomatic gallstones (as detected on screening abdominal ultrasound) to become symptomatic. In addition, the study will characterize the pharmacokinetics of CE-326,597.</brief_summary>
	<brief_title>Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones</brief_title>
	<detailed_description />
	<mesh_term>Cholelithiasis</mesh_term>
	<criteria>Body Mass Index between 3040 kg/m2, inclusive Evidence of asymptomatic cholelithiasis on screening abdominal ultrasound Patients with unstable medical conditions, such as diabetes, stroke, heart attack. Females of childbearing potential or those who may be pregnant or breast feeding. Patients with inflammed gallbladder, evidence of stones in bile ducts on screening abdominal ultrasound, history of symptoms indicating active gallbladder disease or gallbladder removal.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Safety in patients with Asymptomatic cholelithiasis/gallstones.</keyword>
</DOC>